Daily Sepsis Research Analysis
Analyzed 37 papers and selected 3 impactful papers.
Summary
Today’s top sepsis papers span clinical trials, diagnostic criteria, and translational immunobiology. Long-term follow-up of an RCT (CLOVERS/SHAMROC) found no differences in 6–12 month patient-centered outcomes between restrictive versus liberal fluid strategies. A large multicenter analysis comparing SOFA-1 versus updated SOFA-2 shows high concordance but meaningful discordance with mortality implications, and a translational study links low serum cholinesterase to sepsis immunosuppression via the hub gene RORA.
Research Themes
- Fluid resuscitation strategies and long-term patient-centered outcomes in sepsis
- Impact of updated organ dysfunction scoring (SOFA-2) on sepsis identification and prognosis
- Biomarkers and mechanisms of sepsis-associated immunosuppression (serum cholinesterase–RORA axis)
Selected Articles
1. Effects of an early restrictive versus liberal fluid strategy on long-term patient-centered outcomes in sepsis-induced hypotension (SHAMROC): an open-label, randomized controlled trial.
In long-term follow-up of CLOVERS participants with sepsis-induced hypotension, restrictive versus liberal fluid strategies yielded no differences in cognitive function, disability, mobility, or health-related quality of life at 6 and 12 months using 50% trimmed means. Baseline characteristics were balanced and findings were consistent across multiple patient-centered domains.
Impact: This RCT-derived follow-up directly addresses whether early fluid strategy influences sepsis survivors’ long-term recovery and finds no difference, informing a major area of clinical debate.
Clinical Implications: Clinicians can individualize early resuscitation strategy without expecting differences in long-term cognitive, functional, or quality-of-life outcomes; focus may remain on short-term hemodynamics and safety.
Key Findings
- No between-group differences at 6 months in MoCA-Blind (trimmed mean difference 0.11; 95% CI −1.44 to 1.70), executive function, ADL, mobility, or EQ-5D-5L.
- No differences persisted at 12 months across patient-centered outcomes.
- Of 1,563 CLOVERS participants, 898 (57%) entered SHAMROC; 702 were analyzable at 6 months with 196 lost to follow-up.
Methodological Strengths
- Randomized treatment assignment within the PETAL Network CLOVERS platform
- Pre-specified 50% trimmed-mean analyses to address informative censoring by death
Limitations
- Open-label design and substantial loss to follow-up (196 participants)
- Only 57% of original CLOVERS participants were included in the long-term follow-up cohort
Future Directions: Evaluate whether phenotype-guided or vasopressor-prioritized resuscitation affects long-term neurocognitive and functional outcomes; assess subgroups (e.g., chronic kidney disease, heart failure).
RATIONALE: The impact of fluid resuscitation strategies on patient-centered outcomes of sepsis survivors is unknown. OBJECTIVES: To assess the effect of an early restrictive or liberal fluid resuscitation strategy on long-term functional outcomes in patients with sepsis-induced hypotension. METHODS: SHAMROC (Sepsis-induced Hypotension: Assessing effect of Method of Resuscitation On patient-Centered outcomes) prospectively assessed the impact of random assignment to a restrictive or liberal fluid resuscitation strategy for sepsis-induced hypotension outcomes at 6 and 12 months after randomization in the NIH NHLBI PETAL Network's CLOVERS trial (NCT03434028). The pre-specified analyses used trimmed means at 50% to prevent informative censoring of deceased patients. MEASUREMENTS AND MAIN RESULTS: Of the 1563 participants included in the CLOVERS trial, 898 (57%) were included in the SHAMROC trial. As 196 were lost to follow-up, 702 participants were analyzed at 6 months (431 survivors and 271 non-survivors). Baseline characteristics were similar between the groups. At 6 months, no group differences were observed in cognitive function (restrictive versus liberal; trimmed mean difference in Montreal Cognitive Assessment-Blind Score, 0.11, 95% CI -1.44-1.70), executive function (trimmed mean difference in Hayling Sentence Completion Test, 0.38, 95% CI -0.97-1.76), disability status (trimmed mean difference in Activity of Daily Living Score, 0.03, 95% CI -0.84-0.90), mobility (trimmed mean difference in PROMIS Mobility Score, 0.72, 95% CI -2.20-3.64), and health-related quality of life (trimmed mean difference in EQ-5D-5L, -0.01, 95% CI -0.07-0.06). Outcomes also did not differ at 12 months. CONCLUSIONS: In this long-term follow-up of a randomized controlled trial of patients with sepsis-induced hypotension, the restrictive fluid strategy used in this study resulted in similar cognitive and physical function at 6 and 12 months, compared to a liberal fluid strategy.
2. Serum cholinesterase as a biomarker for sepsis-associated immunosuppression via Hub gene RORA.
Serum cholinesterase was reduced in sepsis and correlated with higher APACHE-II/SOFA scores and lower CD4/CD8 T and NK cell counts. Multi-omic analyses identified RORA as a downregulated hub gene across eight datasets, with positive associations to lymphocyte counts; CLP mice showed parallel decreases in cholinesterase and splenic RORA mRNA alongside T-cell depletion. Findings position cholinesterase as a practical immunosuppression biomarker and RORA as a mechanistic link.
Impact: By linking a routinely measured enzyme (serum cholinesterase) to sepsis-associated immunosuppression and identifying RORA as a mechanistic hub, this study advances both biomarker development and therapeutic target discovery.
Clinical Implications: Serum cholinesterase could help monitor immune competence and stratify patients at risk of immunosuppression; RORA-targeted immunomodulation merits exploration but requires clinical validation.
Key Findings
- Serum cholinesterase activity was significantly reduced in sepsis and inversely correlated with APACHE-II and SOFA scores.
- Lower cholinesterase correlated with reduced CD4+ T, CD8+ T, and NK cell counts in patients.
- RORA was consistently downregulated across eight GEO datasets and positively associated with T/NK cell abundance; in CLP mice, decreases in cholinesterase and splenic RORA mRNA paralleled T-cell depletion.
Methodological Strengths
- Translational design integrating human cohort, multi-omic bioinformatics, and CLP mouse validation
- Cross-dataset external validation of RORA across eight GEO datasets
Limitations
- Single-center clinical cohort with observational associations; sample size not specified in abstract
- No interventional testing of RORA modulation; clinical utility of cholinesterase thresholds requires prospective validation
Future Directions: Prospective multicenter validation of cholinesterase-based immune monitoring; mechanistic and pharmacologic studies targeting RORA to reverse sepsis immunosuppression.
BACKGROUND: Sepsis-induced immunosuppression is a key factor contributing to high mortality rates. However, suitable biomarkers for routine clinical monitoring of immune function are currently lacking. Serum cholinesterase levels are markedly diminished in sepsis and are associated with unfavorable prognoses, its role in the immunosuppression pathology and the mechanisms involved remain inadequately understood. METHODS: We conducted a translational study integrating clinical research, bioinformatics analysis and animal experiments. Initially, within a single-center clinical cohort, we investigated the correlation between serum cholinesterase levels and lymphocyte subsets in patients suffering from sepsis, subsequently evaluating its association with disease severity (APACHE-II and SOFA scores) and clinical outcomes. Subsequently, by integrating sepsis transcriptome data with cholinergic anti-inflammatory pathways and immune-related gene sets, we identified the hub gene RORA and validated it across multiple dimensions using public databases. Finally, in the CLP sepsis mouse model, we measured cholinesterase activity and specifically quantified RORA mRNA expression in the spleen. We then analyzed the correlation between these measurements and changes in key immune cell counts. RESULTS: Clinical data revealed significantly reduced serum cholinesterase activity in sepsis patients. Decreased cholinesterase levels positively correlated with elevated disease severity scores (APAChE-II, SOFA) and reduced counts of CD4 ⁺ T cells, CD8 ⁺ T cells, and NK cells. Bioinformatics analysis identified RORA as a hub gene linking sepsis, cholinesterase, and immune responses. Across eight independent GEO datasets, RORA expression exhibited a consistent downregulation trend in sepsis with high diagnostic value. Analysis of immune cell infiltration revealed significant positive correlations between RORA and counts of CD4 ⁺ T, CD8 ⁺ T, and NK cells in sepsis. In the CLP mouse model, reductions in spleen CD3 ⁺ T, CD4 ⁺ T, and CD8 ⁺ T cell counts coincided with notable decreases in serum cholinesterase and spleen RORA mRNA levels. Both serum cholinesterase concentration and spleen RORA mRNA expression exhibited positive correlations with CD4 ⁺ T and CD8 ⁺ T cell counts. CONCLUSION: This study establishes serum cholinesterase as a valuable clinical biomarker for assessing sepsis diagnosis, disease severity, and immunosuppression. For the first time, through multiomics integration and experimental validation, RORA has been identified as the key molecular bridge linking the cholinesterase activity and immunosuppression in sepsis. This not only provides a new direction for understanding immune dysregulation in sepsis but also lays a theoretical foundation for the future development of RORA-targeted immunomodulation and treatment strategies for sepsis.
3. Impact of the updated SOFA-2 score on sepsis diagnosis and prognosis: a retrospective multicenter cohort study.
Across 74,615 ICU patients with suspected infection, SOFA-1 and SOFA-2 agreed in 89.62% yet each uniquely identified additional sepsis cases (SOFA-1: 3.54%; SOFA-2: 6.84%), largely driven by respiratory and renal criterion updates. Discordant groups had higher ICU mortality than non-sepsis, supporting a transitional period using both scores.
Impact: As ICUs transition to SOFA-2, this large real-world analysis shows who is newly captured or missed and links discordance to mortality, directly informing sepsis surveillance, epidemiology, and trial eligibility.
Clinical Implications: Health systems should prepare for shifts in sepsis case identification and consider parallel reporting during transition to SOFA-2; EHR alerts and prognostic tools may need recalibration, especially for respiratory and renal dysfunction.
Key Findings
- Diagnostic concordance between SOFA-1 and SOFA-2 was 89.62% among 74,615 ICU patients.
- SOFA-1 and SOFA-2 uniquely identified 3.54% and 6.84% additional sepsis cases, respectively, driven mainly by respiratory and renal updates.
- ICU mortality: Concordant Positive 15.63%; SOFA-1 Only 8.31%; SOFA-2 Only 9.23%; both discordant groups exceeded non-sepsis mortality (6.71%).
Methodological Strengths
- Very large multicenter cohort spanning three ICU databases across two countries
- Head-to-head comparison of diagnostic performance, timeliness, and outcome associations
Limitations
- Retrospective design with potential misclassification of suspected infection and sepsis onset
- Generalizability limited to participating databases; exact P-value reporting truncated in abstract
Future Directions: Prospective validation of SOFA-2-based sepsis surveillance, recalibration of EHR alerts, and assessment of impact on clinical decision-making and trial enrollment.
BACKGROUND: The Sepsis-3 criteria operationalized organ dysfunction using the original Sequential Organ Failure Assessment (SOFA-1) score, which was updated to SOFA-2 in October 2025 to align with modern intensive care unit (ICU) practices. However, the impact of adopting SOFA-2 for sepsis detection under the Sepsis-3 criteria has not yet been evaluated. METHODS: We conducted a retrospective multicenter cohort study using three large-scale ICU databases from the United States and the Netherlands. Adult patients with suspected infection within 72 h of ICU admission were included. Sepsis was independently identified according to Sepsis-3 criteria, utilizing either the SOFA-1 or SOFA-2 score. We systematically compared diagnostic concordance, the timeliness of sepsis detection, clinical outcomes and predictive performance of prognostic models between the two scoring systems. The primary outcome was ICU mortality, while secondary outcomes included hospital mortality and 28-day survival. RESULTS: The study cohort comprised 74,615 adult patients with suspected infection. The diagnostic concordance of sepsis between SOFA-1 and SOFA-2 reached 89.62%. However, SOFA-1 and SOFA-2 uniquely identified an additional 3.54% and 6.84% of patients as having sepsis, respectively. The diagnostic discrepancies were primarily attributable to updates in respiratory and renal scoring criteria. ICU mortality was highest among the Concordant Positive group (15.63%). Notably, both discordant groups exhibited substantial mortality (SOFA-1 Only: 8.31%; SOFA-2 Only: 9.23%), both of which were significantly higher than those of patients not classified as having sepsis by either score (6.71%; P = .002 and P = 2.87 × 10 CONCLUSIONS: SOFA-1 and SOFA-2 showed high concordance in sepsis detection, yet each identified distinct patient subgroups with significant mortality. A transitional strategy utilizing both SOFA-1 and SOFA-2 is advised until updated expert-validated sepsis criteria are established.